IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
Gastroenterology Learning Network
00:00
New Therapies for IBD: A Trasimod and Mira Kizumab
This chapter explores the effectiveness and safety of a trasimod study compared to anemone, and introduces Mira Kizumab as the first IL-23 inhibitor for ulcerative colitis, providing information on its dosing and administration, as well as its good safety data.
Transcript
Play full episode
